Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797056167701118976 |
|---|---|
| author | Berair, R Pavord, I |
| author_facet | Berair, R Pavord, I |
| author_sort | Berair, R |
| collection | OXFORD |
| description | Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understood. In recent years significant progress has been made in understanding this heterogeneity and eosinophilic asthma has emerged as a potentially clinically important phenotype because treatment with monoclonal antibodies against IL-5 is effective. This has required a change in our understanding of the role of eosinophilic airway inflammation in airways disease and the developments of reliable biomarkers of eosinophilic airway inflammation. We will review these developments and describe the clinical experience so far with treatment with monoclonal antibiotics against IL-5. © 2013 Springer Science+Business Media New York. |
| first_indexed | 2024-03-06T19:19:34Z |
| format | Journal article |
| id | oxford-uuid:199d8259-7bb9-4d0d-8f3b-ec6a96b6be2e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:19:34Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:199d8259-7bb9-4d0d-8f3b-ec6a96b6be2e2022-03-26T10:49:55ZRationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthmaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:199d8259-7bb9-4d0d-8f3b-ec6a96b6be2eEnglishSymplectic Elements at Oxford2013Berair, RPavord, ISevere asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understood. In recent years significant progress has been made in understanding this heterogeneity and eosinophilic asthma has emerged as a potentially clinically important phenotype because treatment with monoclonal antibodies against IL-5 is effective. This has required a change in our understanding of the role of eosinophilic airway inflammation in airways disease and the developments of reliable biomarkers of eosinophilic airway inflammation. We will review these developments and describe the clinical experience so far with treatment with monoclonal antibiotics against IL-5. © 2013 Springer Science+Business Media New York. |
| spellingShingle | Berair, R Pavord, I Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title_full | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title_fullStr | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title_full_unstemmed | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title_short | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| title_sort | rationale and clinical results of inhibiting interleukin 5 for the treatment of severe asthma |
| work_keys_str_mv | AT berairr rationaleandclinicalresultsofinhibitinginterleukin5forthetreatmentofsevereasthma AT pavordi rationaleandclinicalresultsofinhibitinginterleukin5forthetreatmentofsevereasthma |